Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $8.75.

A number of analysts recently commented on the stock. Chardan Capital raised shares of Rani Therapeutics to a “strong-buy” rating in a report on Wednesday, August 26th. Weiss Ratings cut shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Rani Therapeutics in a research report on Friday, August 21st.

Insider Buying and Selling at Rani Therapeutics

In other news, CEO Talat Imran acquired 35,000 shares of the company’s stock in a transaction that occurred on Friday, July 17th. The stock was purchased at an average cost of $0.72 per share, with a total value of $25,200.00. Following the purchase, the chief executive officer directly owned 469,736 shares of the company’s stock, valued at approximately $338,209.92. This trade represents a 8.05% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 26.73% of the stock is currently owned by corporate insiders.

Institutional Trading of Rani Therapeutics

A number of institutional investors have recently bought and sold shares of RANI. Jefferies Financial Group Inc. purchased a new position in shares of Rani Therapeutics in the fourth quarter valued at $40,000. Squarepoint Ops LLC boosted its position in shares of Rani Therapeutics by 155.5% in the 2nd quarter. Squarepoint Ops LLC now owns 41,902 shares of the company’s stock worth $32,000 after buying an additional 25,501 shares in the last quarter. Kestra Private Wealth Services LLC boosted its position in shares of Rani Therapeutics by 4.1% in the 1st quarter. Kestra Private Wealth Services LLC now owns 265,159 shares of the company’s stock worth $195,000 after buying an additional 10,347 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new stake in Rani Therapeutics in the 2nd quarter valued at about $5,703,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

Rani Therapeutics Stock Performance

NASDAQ:RANI opened at $0.80 on Wednesday. Rani Therapeutics has a 1 year low of $0.45 and a 1 year high of $3.87. The stock has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $0.87. The stock has a market capitalization of $111.56 million, a price-to-earnings ratio of -2.96 and a beta of 0.69.

Rani Therapeutics (NASDAQ:RANI) last issued its earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $0.93 million. On average, analysts predict that Rani Therapeutics will post -0.17 EPS for the current year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologic medicines that are traditionally administered by injection or infusion. The company’s platform is designed to use a swallowable, robotic capsule to transport medicine through the stomach and release it in the small intestine, where the drug can be delivered into the body.

Rani’s technology, known as the RaniPill capsule, is intended to address challenges associated with injectable therapies, including the need for administration by a healthcare professional and patient reluctance toward injections.